2020 American Transplant Congress
Long-Term Safety in Epstein-Barr Virus (EBV)-Seropositive Kidney-Only Transplant Recipients Treated with Belatacept (BELA) in Clinical Practice: Final Study Results from the ENLiST Registry
*Purpose: BELA, a selective T-cell costimulation blocker, is approved for the prophylaxis of organ rejection in EBV-seropositive adult kidney transplant recipients. In phase 3 BENEFIT…2020 American Transplant Congress
Evaluation of the Use of Sublingual Tacrolimus in the Inpatient Setting
*Purpose: To determine the efficacy and safety of sublingual (SL) tacrolimus (TAC) administration.*Methods: A single-center, retrospective study was performed on solid organ transplant recipients who…2020 American Transplant Congress
PHS High Risk: Is this Classification Still Needed?
Vanderbilt Transplant Center, Nashville, TN
*Purpose: The continued shortage of organs for the over 100,000 candidates on the waitlist has led transplant centers to consider organs that have historically higher…2020 American Transplant Congress
Monitoring Recipients of Public Health Service (PHS) Increased Risk Donors Using an Electronic Medical Record-Based System
1Yale School of Medicine, New Haven, CT, 2Yale New Haven Health, New Haven, CT
*Purpose: In 2014, the Organ Procurement and Transplantation Network (OPTN) policy was updated, mandating transplant centers to implement a post-transplant screening protocol for transmissible diseases.…2020 American Transplant Congress
Socioeconomic Independence and Kidney Transplantation Outcomes: A Nationwide Study of South Korea
*Purpose: A nationwide study regarding the association between socioeconomic dependency accessibility to or prognosis of kidney transplantation has been rarely studied, particularly in an Asian…2020 American Transplant Congress
Less Bleeding Associated with Apixaban versus Other Direct Acting Oral Anticoagulation in Solid Organ Transplant Recipients
*Purpose: Owing to their fixed dosing and favorable drug interaction profiles, direct acting oral anticoagulants (DOACs) have supplanted warfarin as the standard of care for…2020 American Transplant Congress
Teduglutide Therapy in Real World Setting is Efficacious in Reducing Complications in Short Bowel Syndrome
*Purpose: Teduglutide, a GLP-2 analogue, increases portal and intestinal blood flow thereby increasing absorption of fluid and nutrients. We evaluated outcomes of Teduglutide therapy for…2020 American Transplant Congress
Multi- National Survey among Nephrologists & Transplant Surgeons about the Suitability & Acceptance of the Marginal Living- Kidney Donors with Obesity or Abnormal Blood Sugar Profile
1KAMC, Riyadh, Saudi Arabia, 2Taif University, Taif, Saudi Arabia
*Purpose: There are no clear guidelines about the suitability and acceptance of living- kidney donors with obesity or abnormal blood sugar profile.*Methods: To form a…2020 American Transplant Congress
Efficacy and Safety Outcomes by Donor Type in De Novo Renal Transplant Recipients Receiving Everolimus with Reduced-Dose Calcineurin Inhibitor: 24-Month Results from Transform
1TRANSFORM Study Group, Basel, Switzerland, 2Novartis Pharma AG, Basel, Switzerland
*Purpose: To assess the efficacy and safety outcomes in de novo renal transplant (RTx) recipients receiving everolimus with reduced-exposure calcineurin inhibitor (EVR+rCNI) versus mycophenolate with…2020 American Transplant Congress
Multi- National Survey among Nephrologists & Transplant Surgeons About the Suitability and Acceptance of the Marginal Live Kidney Donors with Sickle Cell Trait
*Purpose: Due to organ shortage, many transplant centers may consider “marginal” kidney donors as those with sickle cell trait ( SCT) for donation. Acceptance of…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 19
- Next Page »